Evidence map›Paper›PMID 27500537›Full record

ReviewPediatric research2016

What is the identity of fibroblast-pneumocyte factor?

George King, Megan E Smith, Max H Cake, Heber C Nielsen

Open access · bronzeAbstract readReview
In one paragraph

Review in Pediatric research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

George KingSchool of Veterinary and Life Sciences, Murdoch University, Perth, Western Australia.
Megan E SmithTufts Medical School, Boston, Massachusetts.
Max H CakeSchool of Veterinary and Life Sciences, Murdoch University, Perth, Western Australia.
Heber C NielsenDepartment of Pediatrics and Graduate Program in Cell, Molecular and Developmental Biology, Tufts Medical School, Boston, Massachusetts.
Murdoch University · AUTufts Medical Center · US

Funding

ErbB Signaling in Fetal Type II Cell GrowthR01HL085648 · NHLBI · TUFTS MEDICAL CENTER · PI DAMMANN, CHRISTIANE E, NIELSEN, HEBER C. · 2009 to 2012
$1.6M
Control of Angiogenesis in neonatal Hyperoxic Lung InjuryR21HL097231 · NHLBI · TUFTS MEDICAL CENTER · PI NIELSEN, HEBER C. · 2011 to 2012
$437k
MINORITY PREDOCTORAL FELLOWSHIP PROGRAMF31HL009730 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SZKLO, MARIANA · 1996 to 2000
$19k
NHLBI NIH HHS F31 HL009730NHLBI NIH HHS R01 HL085648NHLBI NIH HHS R21 HL097231
6 · The paper itself

Abstract

Glucocorticoid induction of pulmonary surfactant involves a mesenchyme-derived protein first characterized in 1978 by Smith and termed fibroblast-pneumocyte factor (FPF). Despite a number of agents having been postulated as being FPF, its identity has remained obscure. In the past decade, three strong candidates for FPF have arisen. This review examines the evidence that keratinocyte growth factor (KGF), leptin or neuregulin-1β (NRG-1β) act as FPF or components of it. As with FPF production, glucocorticoids enhance the concentration of each of these agents in fibroblast-conditioned media. Moreover, each stimulates the synthesis of surfactant-associated phospholipids and proteins in type II pneumocytes. Further, some have unique activities, for example, KGF also minimizes lung injury through enhanced epithelial cell proliferation and NRG-1β enhances surfactant phospholipid secretion and β-adrenergic receptor activity in type II cells. However, even though these agents have attributes in common with FPF, it is inappropriate to specify any one of these agents as FPF. Rather, it appears that each contributes to separate mesenchymal-epithelial signaling mechanisms involved in different aspects of lung development. Given that the production of pulmonary surfactant is essential for postnatal survival, it is reasonable to suggest that several mechanisms independently regulate surfactant synthesis.

Indexed as

Alveolar Epithelial CellsAnimalsCell ProliferationFibroblast Growth Factor 7Fibroblast Growth FactorsGlucocorticoidsHumansLeptinLungNeuregulin-1PhospholipidsPulmonary SurfactantsReceptor, Fibroblast Growth Factor, Type 2Signal TransductionFibroblast Growth Factor 7Fibroblast Growth Factorsfibroblast pneumonocyte factorGlucocorticoidskeratinocyte growth factor receptorLeptinNeuregulin-1PhospholipidsPulmonary SurfactantsReceptor, Fibroblast Growth Factor, Type 2

Identifiers

PMID27500537
PMCPMC5112109
OpenAlexW2505976114

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.